NORTHBROOK, IL -- (MARKET WIRE) -- 09/06/11 -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for Application Serial …
Horizon Pharma Announces Pricing of its Initial Public Offering
NORTHBROOK, IL. – July 28, 2011 – Horizon Pharma, Inc. (Nasdaq: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 …
Horizon Pharma Announces FDA Approval of DUEXIS®(ibuprofen/famotidine) for the Relief of the Signs and Symptoms of Rheumatoid Arthritis and Osteoarthritis and to Decrease the Risk of Developing Upper Gastrointestinal Ulcers
NORTHBROOK, Ill. – April 25, 2011 – Horizon Pharma, Inc., a biopharmaceutical company developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and …